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Abstract
Protein misfolding cyclic amplification (PMCA) has emerged as an important technique for detecting low levels of
pathogenic prion protein in biological samples. The method exploits the ability of the pathogenic prion protein to convert
the normal prion protein to a proteinase K-resistant conformation. Inclusion of TeflonH beads in the PMCA reaction (PMCAb)
has been previously shown to increase the sensitivity and robustness of detection for the 263 K and SSLOW strains of
hamster-adapted prions. Here, we demonstrate that PMCAb with saponin dramatically increases the sensitivity of detection
for chronic wasting disease (CWD) agent without compromising the specificity of the assay (i.e., no false positive results).
Addition of TeflonH beads increased the robustness of the PMCA reaction, resulting in a decrease in the variability of PMCA
results. Three rounds of serial PMCAb allowed detection of CWD agent from a 6.7610
213 dilution of 10% brain homogenate
(1.3 fg of source brain). Titration of the same brain homogenate in transgenic mice expressing cervid prion protein
(Tg(CerPrP)1536
+/2 mice) allowed detection of CWD agent from the 10
26 dilution of 10% brain homogenate. PMCAb is,
thus, more sensitive than bioassay in transgenic mice by a factor exceeding 10
5. Additionally, we are able to amplify CWD
agent from brain tissue and lymph nodes of CWD-positive white-tailed deer having Prnp alleles associated with reduced
disease susceptibility.
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Introduction
Transmissible spongiform encephalopathies (TSEs) or prion
diseases are a class of rare progressive neurodegenerative diseases
and include scrapie in sheep, bovine spongiform encephalopathy
in cattle, and chronic wasting disease (CWD) in deer, elk and
moose, and Creutzfeldt-Jakob disease in humans. The etiological
agents in TSEs lack specific nucleic acid and are referred to as
prions. Substantial experimental evidence indicates that prions are
composed primarily, if not solely, of a disease-associated
conformer of the host-encoded prion protein (PrP) [1,2]. The
central biochemical event in the propagation of prion diseases is
the refolding of the normal cellular prion protein (PrP
C) into a
disease-associated conformer (PrP
TSE), a substantial fraction of
which partially resists digestion by proteinase K (PK) and is
denoted PrP
res. The precise molecular mechanism of PrP
C-to-
PrP
TSE conversion is unknown. Template-assisted refolding and
nucleation-polymerization models have been advanced as mech-
anisms [3,4]. The multiple stable conformations of PrP
TSE lead to
the phenomenon of a single protein being able to encipher
multiple strains.
Protein misfolding cyclic amplification (PMCA) [5] has emerged
as an important technique for detecting low levels of PrP
res in
biological samples [6–8]. PMCA exploits the ability of PrP
TSE to
catalyze the conversion of PrP
C to the misfolded isoform in a
manner conceptually similar to the polymerase chain reaction.
The amount of PrP
res is increased by successive cycles of
sonication (to disrupt PrP
TSE aggregates) and amplification using
PrP
C from brain homogenate as a substrate. Sensitivity can be
increased by replenishing the substrate after a round of PMCA
(one round consists of multiple sonication-amplification cycles).
The level of amplification is typically determined by immunoblot-
ting of the amplification products following PK digestion.
Sensitivity depends on the efficiency of amplification and the
number of PMCA rounds. The lowest detection limit reported for
infected brain homogenate (BH) is a 1610
212 dilution of 10% BH
from Syrian hamsters infected with the 263 K strain of hamster-
adapted scrapie agent [9] carried through seven rounds of PMCA.
This was estimated to be equivalent to ,26 molecules or 1.3 ag of
PrP
TSE [9], a thousand-fold more sensitive than the next most
sensitive method (animal bioassay; 2610
29 dilution of 10% BH or
5.3 fg). The PrP
res generated by PMCA is infectious [10] and
retains the strain properties of the original PrP
TSE seed [11].
Adaptation of agent into a new species using PMCA faithfully
mimics adaptation in vivo [12].
Optimal amplification conditions for PMCA vary by the prion
strain being amplified [10,12,13]. Conditions for highly sensitive
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[10]. For CWD agent (PrP
CWD), continued improvement in
sensitivity has been reported over the past several years [12,14].
Kurt et al. (2007) demonstrated detection of PrP
CWD in a
6.5610
29 dilution of 10% BH, gaining 200-fold increase in
sensitivity with each round of serial PMCA. Meyerett et al. (2008)
reported a 6,666-fold increase in detection with a single-round of
PMCA, but did not report a limit of detection for PrP
CWD from a
BH dilution series. Although we are able to achieve amplification
of PrP
CWD under reported conditions [15], amplification was
inconsistent, with rounds of PMCA intermittently failing to
amplify any PrP
CWD. Such inconsistencies in amplification have
been noted previously [16]. This lack of robustness for PMCA
negatively impacts the usefulness of the technique. Attempts to
remedy these inconsistencies, such as addition of polyA RNA,
have improved the robustness of the technique, but at the
expense of increasing spontaneous generation of PrP
res in the
absence of a PrP
TSE seed [17,18]. This production of false
positives precludes using the technique to screen samples in
which minute levels of disease agent are expected. Recently,
Gonzalez-Montalban et al. (2011) altered the PMCA format by
including TeflonH beads (PMCAb) and observed increased
robustness, rate, and yield of prion protein conversion, improving
the sensitivity of detection for hamster-adapted TSE strains.
Pritzkow et al. (2011) reported that inclusion of glass beads in the
PMCA reaction also increases sensitivity and robustness for
detection of the hamster-adapted 263 K prion strain and
quantitatively linked seeding activity in PMCAb to infectivity in
vivo [19]. In both PMCAb studies, the increases in robustness
were not accompanied by a loss in specificity (i.e., no false
positives), suggesting PMCAb may provide sensitive and robust
amplification of other prion strains.
In this contribution, we demonstrate that PMCAb with TeflonH
beads increases the rate and yield of PrP
CWD amplification, while
maintaining high specificity. The sensitivity of PrP
CWD detection
achieved after three rounds of serial PMCAb was higher than
bioassay in transgenic cervidized mice (Tg(CerPrP)1536
+/2 mice)
by a factor of 10
5. No false positives were generated with this
method through six rounds of PMCAb. The robustness of
amplification with beads was also markedly improved. The
striking improvement in amplification efficiency and robustness
achievable by PMCAb will aid CWD diagnostics, analysis of
CWD disease progression and transmission as well as identification
of environmental reservoirs of infectivity.
Results
TeflonH beads increase amplification rate and yield in
PMCA of PrP
CWD
We evaluated the effect of TeflonH beads (two 2.32 mm beads)
on the yield and rate of CWD agent amplification using the
PMCA reaction conditions reported by Gonzalez-Montalban et al.
(2011). PMCAb generated detectable levels of PrP
res in one 96-
cycle round through the 1.3610
26 dilution (2.5 ng brain)
compared to 1.6610
24 (312.5 ng source brain) in the no-bead
control dilution series (Fig. 1). The primary source of PrP
CWD was
brain tissue from clinically affected CWD-positive wt/wt white-
tailed deer inoculated by the oral route (the wt/wt Prnp genotype is
homozygous for amino acids Q and G at residues 95 and 96,
respectively) [20]. Dilution series were prepared from 10% BH.
Not only did inclusion of TeflonH beads boost the sensitivity of
CWD prion detection by a factor of 125, but densitometric
analysis indicated the yield of PrP
res in the 2610
22 dilution was
boosted by a factor of 7.3 when beads were included. Inclusion of
TeflonH beads also improved the consistency of amplification
results: the highest dilution detected agreed within a factor of five
in five replicate single-round PMCAb experiments with TeflonH
beads. For these experiments, 0.05% saponin was included in the
normal brain homogenate (NBH).
Saponin further increases the rate of PMCAb
amplification
Inclusion of the amphipathic glycosides saponin or digitonin
(0.05%) has been reported to increase the sensitivity of PMCA for
PrP
RML [13] and PrP
CWD [15]. To quantitatively assess the effect
of saponin on PMCAb of PrP
CWD, a series of five-fold dilutions of
the 10% BH was made in NBH lacking saponin. Aliquots (10 mL)
of each dilution were added to 90 mL NBH with or without
0.05% saponin (0.045% final concentration). Samples were
subjected to a single 96-cycle round of PMCAb. Sample location
in the sonicator was changed each time the experiment was
repeated to eliminate potential bias introduced by the position of
sample tubes in the sonicator horn. Following PMCAb, 20 mLo f
each sample was fractionated by SDS-PAGE and immuno-
blotted. Three replicate experiments demonstrated that inclusion
of saponin increased the sensitivity of PMCAb by a factor of five
to 25 (Fig. 2). Interestingly, in the lower dilutions of CWD-
positive BH, the amount of PrP
res produced was similar between
the two dilution series with and without saponin, indicating
that the saponin does not influence the upper limit of PrP
res
produced, but rather the rate of production (data not shown). We
also tested 0.05% digitonin in PMCAb amplification, but did not
observe an increase in detection over saponin (data not shown).
To determine whether the effect of saponin might be attributable
to signal enhancement during Western blotting rather than to
improved amplification, we spiked saponin or an equivalent
amount of phosphate buffered saline into a dilution series that
had undergone one round of PMCAb without saponin. No
increase in detection was observed in the samples spiked with
saponin (data not shown).
Figure 1. TeflonH beads in PMCA reaction increase sensitivity
and yield of PrP
CWD. CWD-positive brain homogenate (BH; 10% w/v)
was serially diluted in normal BH (NBH). A 10 mL aliquot of the seed
dilution was transferred into 90 mL NBH with 0.05% saponin in five-fold
increments and subjected to PMCA (96 cycles) in the presence or
absence of two 2.32 mm TeflonH beads (PMCAb). The no-seed control
was 100 mL NBH treated as the other samples. MWM, molecular weight
marker.
doi:10.1371/journal.pone.0035383.g001
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Tg(CerPrP) mice
To determine the amount of infectious agent in the initial brain
homogenate and to facilitate comparison of the sensitivity of
PMCAb to bioassay, we titered the inoculum (serial 10-fold
dilutions of 10% BH in PBS) in transgenic mice expressing cervid
prion protein (Tg(CerPrP)1536
+/2 mice) [21] via the intracerebral
(i.c.) route of exposure. For the 10
27 dilution of BH, mice were
euthanized after one year in the absence of signs of clinical disease,
and four of eight mice exhibited PrP
res in brain tissue
(Supporting Fig. S1). All mice (8/8) receiving the 10
26 dilution
of CWD-positive BH exhibited clinical signs of ataxia, head
tremors and, in some cases, mild kyphosis. Time to onset of clinical
signs was 487642 days for the 10
26 dilution of the inoculum.
Based on this bioassay, log titer was estimated using the Ka ¨rber
equation M=xr2d(S920.5), where M is the estimated ID50, xr is
the highest dilution at which all mice succumbed to disease, d is the
log-dose interval (10 in this case), and S9 is the sum of positive
frequencies from the last dilution that is 100% positive through to
the highest dilution. Because the animals receiving the highest
dilution were euthanized prior to manifestation of clinical
symptoms, we excluded them from the calculation yielding a
conservative estimate of 6.5 log i.c. ID50?30 mL
21 10% BH or 9.0
log i.c. ID50?g
21.
To compare the sensitivity achievable by PMCAb to that of
bioassay, serial 5-fold dilutions of CWD-positive 10% BH in NBH
were prepared, generating 2610
22 to 4.2610
217 dilutions. Each
dilution was then subjected to serial PMCAb. After three rounds of
serial PMCAb, PrP
res was detectable in the 6.7610
213 dilution of
10% BH (1.3 fg of source brain) (Fig. 3a) with no further gain in
sensitivity with a fourth round of PMCAb, as indicated by no
signal in higher dilutions (Fig. 3b). The sensitivity of PMCAb in
three serial 96-cycle rounds was thus higher than that of bioassay
in cervidized Tg mice by a factor exceeding 10
5.
High PMCAb sensitivity prompted concern that PrP
res might
be generated spontaneously, producing false positive results. To
investigate this possibility, we seeded 11 samples with CWD-
negative deer BH (10% w/v) and performed six 96-cycle rounds
of serial PMCAb. No PrP
res was detectable by immunoblotting
after six rounds of PMCAb (Fig. 4). A positive control was
carried through the six rounds of PMCAb to verify that
amplification conditions were achieved. For all no-seed controls
performed, no PrP
res was detected, this included 18 single-round,
seven two-round, five three-round, and four four-round PMCAb
reactions.
Figure 2. Saponin increases the sensitivity of PMCAb for
PrP
CWD detection. CWD-positive brain homogenate (BH; 10% w/v)
was diluted using serial five-fold dilutions in NBH and subjected to one
round of 96-cycle PMCAb in the presence of absence of 0.045%
saponin. BH, brain homogenate; MWM, molecular weight marker.
doi:10.1371/journal.pone.0035383.g002
Figure 3. Serial PMCAb allows detection of PrP
CWD from
femtogram levels of infected brain. CWD-positive BH (10% w/v)
was diluted using serial five-fold dilutions in NBH and subjected to serial
PMCAb in the presence of 0.05% saponin for four 96-cycle rounds.
Results from the (A) third and (B) fourth rounds are shown. No-seed
controls contained 100 mL NBH. MWM, molecular weight marker.
doi:10.1371/journal.pone.0035383.g003
Figure 4. Serial PMCAb has high specificity. Eleven 10 mL CWD-
negative white-tailed deer, homozygous for the wild-type Prnp, gene
brain homogenate (BH; 10% w/v) samples (lanes 1–11) or 10 mL
3.2610
212 dilution of wt/wt CWD+ white-tailed deer BH (lane 13) was
added to 90 mL NBH with 0.05% saponin and subjected to six successive
rounds of 96-cycle PMCAb. Samples from the sixth round were digested
with proteinase K (PK; 50 mg?mL
21 final concentration) for 1 h at 37uC
except one no-PK control.
doi:10.1371/journal.pone.0035383.g004
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The composition of the beads used in PMCAb can affect
amplification efficiency, and the optimal bead material appears to
vary by prion strain [16]. We tested the effect of bead material on
the amplification of PrP
CWD. Polymeric bead materials, previously
shown to enhance amplification of rodent-adapted prions,
(TeflonH, EPDM, acetal, and nylon; [16]) as well as aluminum
oxide (Al2O3) were tested. Glass and steel beads were not tested
because they did not facilitate PrP
res amplification of rodent prion
strains under similar PMCAb conditions [16], although in a
different system smaller glass beads aided amplification [19].
CWD-positive 10% BH was diluted 6,250-fold in NBH and
subjected to PMCAb using each bead material, or a no-bead
control, for one 96-cycle round. Aluminum oxide, nylon and
TeflonH all promoted amplification, while the other bead materials
did not (Supporting Fig. S2). TeflonH beads resulted in the
strongest enhancement of amplification.
Kinetics of CWD prion amplification by PMCAb
The number of cycles per PMCAb round impacts the amount
of PrP
res generated in each round. Maximal amplification of the
263 K strain of hamster-adapted scrapie was achieved using 48-
cycle PMCA rounds [16]. Using these conditions, we observed
only a 5- to 25-fold increase in PrP
res per round in PMCAb of
PrP
CWD (data not shown). To further explore the kinetics of PrP
res
production in PMCAb amplification of PrP
CWD, we prepared four
replicate 4610
23 and 1.6610
24 dilution PMCAb reactions and
removed one tube from each dilution after 24, 48, 72 and 96 cycles
of PMCAb (Fig. 5). Densitometric measurement of the bands on
the resulting immunoblots (ImageJ software) indicated that the
band intensity for the 4610
23 dilution was below detection at 24
cycles and the subsequent bands on the immunoblot increased in
intensity with cycle number. For the 1.6610
24 dilution, PMCAb
did not produce detectable PrP
res until 96 cycles with band
intensity similar to that of the 48-cycle band of the 4610
23
dilution. If we use the 48-cycle band of the 4610
23 dilution as a
baseline, PrP
res accumulation increased by a factor of three by
cycle 72 (an 0.125-fold average increase in intensity per cycle for
the 24 cycles) and by a factor of 5.5 between cycles 48 and 96 (a
0.076-fold average increase per cycle over the last 24 cycles). The
intensity of the cycle 96 band of the 4610
23 dilution was 6.2 times
higher than that of the cycle 96 band of the 1.6610
24 dilution. If
amplification rates were the same for the two dilutions, the band
intensity would be expected to be 25-fold higher.
Amplification of PrP
CWD from white-tailed deer differing
in Prnp genotype and in non-brain tissues
Nucleotide polymorphisms in cervid Prnp alleles are associated
with differential susceptibility to disease transmission and rates of
disease progression in infected animals [20,22–27]. In white-tailed
deer, 95H and 96S alleles are associated with reduced suscepti-
bility to CWD and slower disease progression in infected animals
[16,26]. We examined whether PrP
C from Tg(CerPrP)1536
+/2
mice, which express the wt PrP allele, could support amplification
of PrP
CWD from CWD-positive white-tailed deer expressing at
least one copy of a resistance-associated allele. Serial five-fold
dilutions were made in NBH of wt/wt, wt/95H, wt/96S, and
95H/96S CWD-positive deer brains from clinically affected
animals [20], and 10 mL aliquots of the 4610
23, 1.6610
24 and
6.3610
26 dilutions were used to seed 90 mL fresh NBH. Samples
underwent 96 cycles of PMCAb, reaction mixtures were treated
with PK (50 mgNmL
21), and PrP
res was detected by immunoblot-
ting. NBH from Tg(CerPrP)1536
+/2 mice supported amplification
from all four allelic combinations (Fig. 6) with all three dilutions
amplifying to detectable levels in the wt/wt and wt/95H seeded
reactions. The wt/96S- and 95H/96S-seeded reactions also
supported amplification. We obtained brain tissue from two
hunter-harvested CWD-positive white-tailed deer homozygous for
the 96S allele and prepared 10% (w/v) BH in PMCA buffer. We
also prepared 5% homogenates of lymph nodes from hunter-
harvested 96S homozygous deer and a wt/wt deer, both CWD-
positive. After one 96-cycle round of PMCAb, PrP
res was
detectable in all samples. (Fig. 6B).
Discussion
The present study demonstrates that inclusion of TeflonH beads
and saponin in the PMCA reaction dramatically improves the
sensitivity and robustness of PrP
CWD detection. The sensitivity
achieved by these modifications makes PMCAb detection of CWD
agent comparable to that reported for the 263K and Hyper strains
of hamster-adapted prions [9,16]. Attaining amplification of levels
of PrP
CWD,1 i.c. ID50 in two rounds and at the limit of
immunoblotting detection after three rounds of PMCAb mini-
mizes opportunities for cross-contamination by reducing sample
handling and markedly reducing the time of analysis when
attempting to detect minute levels of CWD agent.
The improved sensitivity and robustness of PMCAb for CWD
agent does not compromise the specificity of the assay. The
method has demonstrated high specificity; no false positives have
been produced, even when performing six rounds of amplification
in serial PMCAb. This specificity is consistent with that observed
for hamster-adapted prion strains [16], and suggests that PMCAb
will be useful in detecting prions from multiple species and in
environmental matrices. With one exception, the PMCAb
reactions reported here used PrP
CWD derived from brain tissue.
Infectious agent derived from other tissues or environmental
matrices may contain compounds that promote non-specific
conversion of PrP
C to PrP
res or inhibit PMCA. Confident
application of PMCAb to diverse sample types requires rigorous
assessment of this possibility.
TeflonH beads and the amphipathic glycoside saponin appear to
have an additive effect on CWD agent amplification, with the
influence of the beads being stronger. At present, the mechanisms
by which these components increase amplification are unknown.
TeflonH beads have been shown to facilitate the fragmentation of
Figure 5. Kinetics of CWD amplification using PMCAb. Four
10 mL samples of 4610
23 or 1.6610
24 dilutions of CWD-positive BH
(10%) were added to 90 mL NBH containing 0.05% saponin and
subjected to PMCAb for the indicated number of cycles.
doi:10.1371/journal.pone.0035383.g005
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for PMCAb varies by prion strain and the number of beads does
not substantially affect conversion efficiency, suggesting that
physical agitation of the reaction mixture by the beads does not
provide an adequate explanation for the mechanism by which
beads facilitate fragmentation of PrP fibrils. The effect of bead
material on energy distribution in the reaction vessel or on the
adsorption of PrP or cofactors may warrant investigation. The
generally low affinity of biomolecules for TeflonH, however, argues
against the importance of the latter. Saponin disrupts cholesterol-
rich lipid rafts, thus promoting conversion efficiency by increasing
the dispersion of PrP
C [13,28].
The source of PrP
C for PMCAb conversion in our study was
BH from perfused Tg(CerPrP)1536
+/2 mice [21]. This mouse line
has been used extensively for both in vivo and in vitro studies of
CWD, making it ideal for characterizing our CWD agent source.
We titered the CWD agent used in this study in Tg(CerPrP)1536
+/
2 mice and determined that 30 mL of the 10
27 dilution of 10%
(w/v) BH transmitted biochemical hallmarks of disease to half of
the mice inoculated. We note that the 10
27 dilution represented
the highest dilution used. If the presence of PrP
res in these mice is
sufficient evidence for infection, then 0.3 ng of clinically affected
CWD-positive white-tailed deer brain contains ,1I D 50 as assayed
in Tg(CerPrP)1536
+/2 mice. This corresponds to 9.5 log i.c.
ID50Ng
21 and agrees with Ka ¨rber method for estimation of titer if
the 10
27 dilution is included, exceeding the levels of infectivity
previously reported for other CWD agent sources characterized in
this mouse line [29,30]. The highest previously reported titer for
CWD was 8.5 log i.c. ID50?g
21 from a mule deer inoculum into a
different cervidized mouse line, Tg(ElkPrP) mice [31]. At least two
factors may have contributed to this difference. First, the CWD
agent used in the present study derived from experimentally
infected white-tailed deer housed in animal care facilities, which
may have facilitated longer survival times with higher accumula-
tion of disease agent. Second, the CWD agent present in
Wisconsin white-tailed deer may result in higher accumulations
of PrP
CWD compared to the levels accumulated in CWD-positive
mule deer.
The sensitivity of serial PMCAb was higher than that of
bioassay in Tg(CerPrP)1536
+/2 mice: serial PMCAb allowed
detection of the 6.7610
213 dilution of 10% CWD-positive BH
after three rounds while biochemical hallmarks of disease were
detected in half of the mice inoculated at the 10
27 dilution.
Thousand-fold increases in sensitivity over bioassay have been
reported for serial PMCA of hamster-adapted prions [9], but the
.10
5 increase is unprecedented.
Figure 6. PMCAb amplifies PrP
CWD from white-tailed deer with allelic variations and from non-CNS tissues. Brain homogenates (BH;
10% w/v) from CWD-positive deer with allelic variations of Prnp were tested for their ability to seed PMCAb. CWD-positive 10% BH from (A) wt/wt or
wt/95H deer and (B) wt/96S or 95H/96S white-tailed deer were serially diluted in normal BH (NBH) from Tg(CerPrP)1536
+/2 mice, and 10 mL of the 25-,
625- and 1.6610
4-fold dilutions from each were used to seed 90 mL fresh NBH and subjected to one 96-cycle PMCAb round. (C) For testing the
homozygous 96S allelic variant, retropharyngeal lymph nodes (LN) or BH from two separate hunter-harvested CWD-positive deer were used to seed
NBH for PMCAb. As controls, homogenates of lymph nodes from a hunter-harvested CWD-positive wt/wt deer or orally inoculated wt/wt CWD
clinically affected deer was used to seed a 96-cycle round of PMCAb. (D) Immunoblotting three five-fold dilutions of 10% BH from the end-stage wt/
wt deer used for these studies after proteinase K digestion demonstrates that the PrP
CWD concentrations used in the PMCAb reactions (Fig. 6A) were
not detectable without amplification.
doi:10.1371/journal.pone.0035383.g006
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and demonstrates that this method is substantially more sensitive
than animal bioassay. The higher sensitivity and increased
robustness of PMCAb is expected to allow early stages of disease
to be delineated (i.e., PrP
TSE trafficking during initial exposure),
determination of efficacies of decontamination methods, and
detection of CWD agent in naturally contaminated environmental
samples. Enabling the identification of environmental reservoirs of
infectivity would lead to better understanding of CWD epizootics.
Materials and Methods
Ethics Statement
All animals were cared for in accordance with protocols
approved by the Institutional Animal Care and Use Committee
of the University of Wisconsin, Madison (Assurance Number
A3464-01).
Preparation of CWD-infected tissue homogenates
CWD-infected BH (10% w/v) in phosphate buffered saline
(PBS) was prepared from whole brain of orally inoculated clinically
affected white-tailed deer (Odocoileus virginianus). The CWD-positive
deer had the following Prnp genotypes: wt/wt, wt/95H, 95H/96S,
or wt/96S [20]. Although most experiments were performed using
the wt/wt CWD-positive BH, tissue homogenates also were
prepared from hunter-harvested, immunohistochemistry-positive
96S/96S white-tailed deer retropharyngeal lymph node (5% w/v)
and obex (10% w/v) in PMCA buffer (described below) or wt/wt
white-tailed deer lymph node (5% w/v).
Determining CWD agent titer in transgenic (CerPrP) mice
Brain homogenate (10% w/v) from a CWD-positive wt/wt
white-tailed deer brain was briefly sonicated (10 s) at 70% intensity
in a cup horn sonicator and serially diluted in PBS to produce
inocula ranging from 10% to 0.000001% w/v BH. Ten transgenic
mice (27–35 days old) expressing cervid prion protein
(Tg(CerPrP)1536
+/2 mice [21]) per dilution were intracerebrally
inoculated with 30 mL inoculum and monitored weekly for disease
symptoms. Upon manifestation of early symptoms (slight ataxia in
the hind limbs), mice were monitored three times weekly for
disease progression. Mice were euthanized when pronounced
ataxia and head tremors were noted, but before notable weight
loss. In a few mice, mild kyphosis developed. Tg(CerPrP)1536
+/2
mice are prone to tumors and only eight mice survived to manifest
clinical symptoms in each cohort except the 0.1% dilution in
which all 10 mice survived to the clinical stage.
Protein misfolding cyclic amplification (PMCA)
Uninfected Tg(CerPrP)1536
+/2 mice, age 4–10 months, were
euthanized by CO2 asphyxiation and immediately perfused with
modified Dulbecco’s phosphate buffered saline without Ca
2+ or
Mg
2+ (Thermo Scientific #SH30028.02) amended with 5 mM
EDTA. Brains were then rapidly removed, flash frozen in liquid
nitrogen, and stored at 280uC until use. Brains were homogenized
on ice to 10% w/v using a Wheaton Potter-Elvehjem homogenizer
in PMCA conversion buffer (Fisher Sci. #0841414C). The
conversion buffer consisted of Ca
2+- and Mg
2+-free DPBS
supplemented with 150 mM NaCl, 1% Triton X100, 0.05%
saponin (Mallinckrodt #H277-57), 5 mM EDTA, and 1 tablet
Roche Complete EDTA-free protease inhibitors cocktail (Fisher
Sci. # 50-720-4069) per 50 mL conversion buffer. In some
experiments, the saponin was omitted or replaced with 0.05%
digitonin (Sigma # D-5628). Brain homogenates were clarified by
centrifugation (2 min, 2,000 g). Supernatant was transferred to
pre-chilled microcentrifuge tubes, flash frozen in liquid nitrogen,
and stored at 280uC until use.
Seeds for PMCA and PMCAb were prepared from clinically
affected CWD-positive white-tailed deer by 1:1 dilution of 20%
(w/v) BH in PBS with the conversion buffer described above. The
resulting 10% BH was serially diluted five-fold in normal brain
homogenate to generate dilution series ranging from 2610
22 to
4.2610
217. Seeds for PMCAb from hunter-harvested obex and
lymph nodes were made by homogenizing tissues in 1:1 mixture of
DPBS and conversion buffer described above, to a final
concentration of 10% (w/v).
The dilutions (10 mL) were used to seed 90 mL NBH in 0.2 mL
thin-walled PCR tubes with (PMCAb) or without (PMCA) two
2.38 mm beads. The majority of PMCAb experiments employed
TeflonH beads (McMaster-Carr, #9660K12). Beads made of other
materials were tested for their effect on conversion efficiency:
nylon (#B000FMUECC), acetal (ball grade 1, #B000FN0OP8),
EPDM (#B00137UR7A), and aluminum oxide (grade 10,
#BAO09310) (Small Parts, www.smallparts.com). Experimental
tubes were placed in a rack in a Misonix S-3000 or S-4000
microplate horn, and the reservoir was filled with 300 mL water.
PMCA and PMCAb conditions consisted of 96 cycles in a Misonix
S-3000 or Misonix S-4000. Each cycle consisted of 30 s sonication
at 50% to 70% of maximum power followed by 29 min 30 sec
incubation at 37uC. With time, individual sonicators required
adjustments in sonication energy delivered. For the Misonix S-
4000, the optimal power for CWD amplification was 125–135 W.
For serial PMCAb, at the conclusion of one 96-cycle round of
PMCAb, 10 mL of each dilution was transferred to 90 mL fresh
NBH and subjected to another 96-cycle round of PMCAb.
Detection of PrP
res by immunoblotting
We prepared PMCA samples for immunoblotting by a method
adapted from Haley et al., (2009). Briefly, 20 mL of each PMCA
reaction was transferred to a thin-walled 96-well plate and mixed
with 3 mL PK (500 mgm L
21) and 7 mL dilution buffer (0.1% [v/
v] Triton-X 100, and 4% (w/v) SDS in PBS) and incubated for
1 h at 37uC with shaking (500 rpm). Following PK digestion,
10 mL4 6 LDS sample buffer (Invitrogen, #NP0008) containing
200 mM DL-1,4-dithiothreitol (Fisher Scientific, #AC16568-0050)
was added, and the sample was incubated for 25 min at 99uC with
shaking (600 rpm). Proteins in 16 or 28 mL samples (and in 4 and
5 mL no-PK controls) were fractionated on 15-well 10% Bis-Tris
Gels (Invitrogen, #NP0303BOX) or 12-well 12% Bis-Tris Gels
(Invitrogen, #NP0342BOX), respectively, and electrotransferred
to polyvinylidene fluoride (PVDF) membranes (Millipore,
#IPVH00010). The PVDF membranes were blocked for 1 h in
3% (w/v) powdered nonfat-milk in TBST prior to application of
mAb 8G8 (1:1,000 in 3% milk TBST; Cayman Chemicals,
#189760). Membranes were rinsed with TBST, and horseradish
peroxidase conjugated goat anti-mouse IgG (Bio-Rad #170-5047)
1:20,000 dilution in 5% milk TBST was applied. After rinsing the
membranes with TBST, ECL Plus immunoblot detection system
(GE Healthcare, #RPN2132) or Supersignal West Pico chemilu-
minescent substrate (Thermo Scientific, #34080) was used to
detect immunoreactivity.
Densitometry
ImageJ software was used for densitometric analysis. Blots were
scanned at 300 dpi and saved as *.tif files. The densitometric
analysis was conducted following the procedure of Miller (www.
lukemiller.org/ImageJ_gel_analysis) and represented an adapta-
tion of the procedure outlined in the imageJ documentation
(http://rsb.info.nih.gov/ij/docs/menus/analye.html#gels). No
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was used as the standard, and other bands expressed as fold
changes from that band.
Supporting Information
Figure S1 PrP
CWD present in brains of Tg(CerPrP)1536
+/2
mice inoculated intracerebrally with a 10
7 dilution of 10%
w/v CWD-positive BH. Mice were euthanized prior to
manifestation of clinical symptoms, and their brains were assayed
for PrP
res by Western blotting. Samples were treated with PK, a
20 mL aliquot of each sample was resolved on a 12-well 12% Bis-
Tris gel and visualized by Western blotting using mAb 8G8 and
goat anti-mouse HRP conjugated secondary Ab. Lane 1 is an
uninfected control Tg(CerPrP)1536
+/2 mouse, lane 3 is from a
clinically positive Tg(CerPrP)1536
+/2 mouse from the 10
2 dilution
of CWD-positive 10% BH and lanes 5–12 are from the
Tg(CerPrP)1536
+/2 mice receiving the 10
7 dilution of CWD-
positive 10% BH.
(TIF)
Figure S2 Teflon beads allow the largest amplification
of CWD associated PrP
res during PMCAb. Teflon beads
were tested against beads of other material (all 2.38 mm) in one
round of PMCAb consisting of 96 cycles. CWD+ brain
homogenate (BH; 10%) was diluted 6,250-fold in normal BH
(NBH), and a 10 mL aliquot was added to 90 mL fresh NBH in
tubes containing no beads, or two EPDM, aluminum oxide, acetal,
nylon or Teflon beads. After PMCAb, samples were digested with
proteinase K (PK; 50 mgNmL
21 final concentration) for 1 h at
37uC. A 28 mL aliquot of each sample (5 mL for the no PK control)
were resolved on a 12 well 12% Bis-Tris gel and visualized by
immunoblotting using mAb 8G8 and goat anti-mouse HRP
conjugated secondary Ab. MWM, molecular weight marker.
(TIF)
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